Athersys has made progress on a number of clinical and commercial fronts in the first months of 2016. Most recently, it reported a one-year follow-up from the Phase II stroke trial, which showed that patients receiving MultiStem improved significantly more than placebo over the course of the year. Also, Athersys and Healios K.K. announced a partnership to commercialize MultiStem in Japan for ischemic stroke with the option to develop other indications. The company expects to initiate a stroke
04 Mar 2016
A bigger, better Japanese partnership
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A bigger, better Japanese partnership
Athersys has made progress on a number of clinical and commercial fronts in the first months of 2016. Most recently, it reported a one-year follow-up from the Phase II stroke trial, which showed that patients receiving MultiStem improved significantly more than placebo over the course of the year. Also, Athersys and Healios K.K. announced a partnership to commercialize MultiStem in Japan for ischemic stroke with the option to develop other indications. The company expects to initiate a stroke